Claims
- 1. (canceled)
- 2. A method of treating or preventing an L-selectin-mediated condition in a subject, comprising administering to said subject an oligosaccharide L-selectin antagonist that inhibits the binding of L-selectin to a MECA-79 antigen.
- 3. The method of claim 2, wherein said L-selectin antagonist comprises the oligosaccharide Galβ1→β4(SO3→6)GlcNAcβ1→3Galβ1→3GalNAc.
- 4. The method of claim 3, wherein said L-selectin antagonist comprises NeuNAcα2→3Galβ1→4[sulfo→6(Fucα1→3)GlcNAc]β1→3Galβ1→3GalNAcα1.
- 5. The method of claim 3, wherein said L-selectin antagonist comprises two or more of the oligosaccharide Galβ1→4(SO3→6)GlcNAcβ1→3Galβ1→3GalNAc.
- 6. The method of claim 4, wherein said L-selectin antagonist comprises two or more of the oligosaccharide NeuNAcα2→3Galβ1→4[sulfo→6(Fucα1→3)GlcNAc]β1→3Galβ1→3GalNAcα1.
- 7-10. (canceled)
- 11. The method of claim 2, further comprising reducing the expression or activity of L-selectin sulfotransferase-2(LSST-2) in said subject.
- 12-29. (canceled)
Government Interests
[0001] This application was made with government support under CA 71932, CA 48737 and CA 33000 awarded by the National Institutes of Health. The government has certain rights in the invention.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09569320 |
May 2000 |
US |
Child |
10841707 |
May 2004 |
US |